Super Religare Laboratories

The British company expects to report "substantial growth" in its food intolerance testing line for full-year 2009, and sales of its microarray-based Genarrayt platform are expected to rise 44 percent to £1.04 million from £72,000 in 2008.

So far this year, Rosetta has found commercialization partners for the diagnostics in the Middle East, Canada, the US, and India.

The arrangement gives Super Religare the rights to distribute the tests in India, Saudi Arabia, Qatar, and the United Arab Emirates.

SRL will distribute Rosetta’ Genomics’ microRNA cancer tests in India, Saudi Arabia, Qatar, and in the UAE.

The service is SRL's first array-based test and could foreshadow the adoption of more array-based diagnostics by the Indian testing giant.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.